CERENO SCIENTIFIC AB B (4A1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CERENO SCIENTIFIC AB B (4A1) has a cash flow conversion efficiency ratio of -0.151x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.03 Million ≈ $-44.46 Million USD) by net assets (€252.47 Million ≈ $295.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CERENO SCIENTIFIC AB B - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how CERENO SCIENTIFIC AB B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CERENO SCIENTIFIC AB B total liabilities for a breakdown of total debt and financial obligations.
CERENO SCIENTIFIC AB B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CERENO SCIENTIFIC AB B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mountain & I Acquisition Co Corp
NASDAQ:MCAA
|
-0.001x |
|
Wam Research Ltd
AU:WAX
|
0.017x |
|
Polight ASA
OL:PLT
|
-0.042x |
|
HomesToLife Ltd
NASDAQ:HTLM
|
0.288x |
|
1Stdibs.Com Inc
NASDAQ:DIBS
|
0.013x |
|
CI Games SA
WAR:CIG
|
0.016x |
|
Midnight Sun Mining Corp
V:MMA
|
-0.178x |
|
Tectonic Metals Inc
V:TECT
|
-0.483x |
Annual Cash Flow Conversion Efficiency for CERENO SCIENTIFIC AB B (2021–2025)
The table below shows the annual cash flow conversion efficiency of CERENO SCIENTIFIC AB B from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of CERENO SCIENTIFIC AB B.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €252.47 Million ≈ $295.17 Million |
€-111.86 Million ≈ $-130.78 Million |
-0.443x | +17.78% |
| 2024-12-31 | €191.93 Million ≈ $224.38 Million |
€-103.42 Million ≈ $-120.91 Million |
-0.539x | -215.92% |
| 2023-12-31 | €216.42 Million ≈ $253.02 Million |
€-36.92 Million ≈ $-43.16 Million |
-0.171x | -84.64% |
| 2022-12-31 | €201.51 Million ≈ $235.59 Million |
€-18.62 Million ≈ $-21.76 Million |
-0.092x | -19.59% |
| 2021-12-31 | €170.06 Million ≈ $198.82 Million |
€-13.14 Million ≈ $-15.36 Million |
-0.077x | -- |
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an … Read more